Ionis Pharmaceuticals, Inc.
NASDAQ:IONSBiotechnology
+$1.22 today
- Market cap
- $4.56B
- Beta
- 0.37
- P/E (TTM)
- -37.5
- EPS (TTM)
- -$1.98
Volume 3.23M
Average 1.83M
IONS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Ionis Pharmaceuticals, Inc.NASDAQ: IONS
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization growth accelerates
Q3 FY2026 depreciation & amortization of $10.63M rose 136.1% year over year, ahead of the +36.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 209.6% from the prior quarter. Over 3 fiscal years it compounded at +0.9% a year.
Context
- Depreciation & amortization amounted to 2.4% of revenue in FY2025, down 0.7 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +136.1% holds above the trailing-twelve-month pace of +36.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 22.69M USD
- Year-over-year change
- +3.2%
- 4-year CAGR
- +3.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.69M | +3.2% |
| FY2024 | 2024-12-31 | 21.99M | -2.3% |
| FY2023 | 2023-12-31 | 22.5M | +1.8% |
| FY2022 | 2022-12-31 | 22.11M | +13.0% |
| FY2021 | 2021-12-31 | 19.56M | — |
Depreciation & Amortization vs competitors
How IONS compares with its peers on the latest reported figures
- IONS's LTM Sep 2026 depreciation & amortization of $28.19M is the 6th largest of the 9 companies compared; the peer median is $49.95M.
- Its year-over-year change of +36.7% is the 3rd highest of 9, against a peer median of +5.3%.
- Depreciation & amortization amounts to 2.9% of revenue for IONS, versus a peer median of 3.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $244.53B | +295495.6% | -7.9% | 23.8% | |
| LTM Jun 2026 | $842.9M | +13.2% | +14.6% | 8.5% | |
| LTM Jun 2026 | $55.3M | +97.1% | -33.0% | 5.5% | |
| LTM Jun 2026 | $54.76M | -3.1% | +7.8% | 1.1% | |
| LTM Mar 2026 | $45.14M | +15.9% | +2.1% | 2.1% | |
| LTM Sep 2026 | $28.19M | +36.7% | +0.9% | 2.9% | |
| LTM Mar 2026 | $13.62M | -61.8% | +24.3% | 2.0% | |
| LTM Mar 2026 | $9.99M | -2.7% | +10.7% | 15.1% | |
| LTM Jun 2026 | $5.07M | -7.9% | -7.1% | 0.7% | |
| Peer median (excluding IONS) | $49.95M | +5.3% | +4.9% | 3.8% | |
Competitors are the stored peer set for IONS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.6M) | (269.72M) | (366.29M) | (453.9M) | (381.39M) |
| Depreciation & Amortization | 19.56M | 22.11M | 22.5M | 21.99M | 22.69M |
| Deferred Income Tax | 25.31M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 120.68M | 100.26M | 105.81M | 130.2M | 133.87M |
| Change in Working Capital | (113.82M) | 7.57M | (77.26M) | (209.39M) | (51.22M) |
| Accounts Receivables | 5.05M | 36.36M | (72.06M) | 5.59M | 26.13M |
| Inventory | (2.84M) | 2.77M | (6.39M) | (5.07M) | (13.67M) |
| Accounts Payables | (6M) | 1.09M | 8.12M | 15.99M | (15.36M) |
| Other Working Capital | (110.03M) | (32.65M) | (6.93M) | (225.9M) | (48.31M) |
| Other Non-Cash Items | 7.67M | (134.59M) | 7.73M | 10.15M | 7.45M |
| Operating Cash Flow | 30.8M | (274.37M) | (307.51M) | (500.95M) | (268.58M) |
| Capital Expenditures | (17.9M) | (20.1M) | (28.01M) | (45.28M) | (51.44M) |
| Acquisitions (Net) | 5.95M | 254.08M | 22K | 0 | 0 |
| Purchases of Investments | (1.13B) | (1.49B) | (1.77B) | (1.85B) | (1.92B) |
| Sales of Investments | 1.34B | 989.15M | 1.58B | 1.77B | 1.7B |
| Other Investing Activities | (5.95M) | 0 | (4.21M) | (5.06M) | (5.64M) |
| Investing Cash Flow | 194.91M | (262.64M) | (214.13M) | (134.03M) | (277.78M) |
| Debt Repayment | 313.57M | (50.69M) | 86.9M | (44.67M) | 483.24M |
| Common Stock Issued | 85.71M | 6.37M | 49.44M | 522.73M | 192.6M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (153.35M) | (10.98M) | 507.74M | 0 | 0 |
| Financing Cash Flow | 245.93M | (55.3M) | 644.08M | 478.06M | 675.84M |
| Effect of Forex Changes | (111K) | (418K) | 352K | (273K) | 702K |
| Net Change in Cash | 471.53M | (592.72M) | 122.79M | (157.19M) | 130.18M |
| Free Cash Flow | 12.9M | (294.47M) | (335.52M) | (546.23M) | (320.03M) |
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
Intrinsic Alpha fair value
Locked
Current Price
$27.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.